SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is seeing heightened investor attention following a positive fireside chat at the CIBC Technology & Innovation Conference, where leadership highlighted profitable growth and a strong backlog in the QNX and secure communications divisions. The community is actively discussing the company's evolving role in the physical AI and robotics sectors, with many investors debating the long-term potential of the QNX operating system as a foundational element in high-performance edge computing.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to a government-backed funding initiative, fueling intense debate between bulls anticipating a potential short squeeze and skeptics raising concerns over extreme valuations and dilution. The stock's volatile price action has triggered widespread community discussion regarding the sustainability of the rally and the impact of the newly announced capital injection on future growth.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing and several peers in the quantum sector are rallying on news that the U.S. government is committing roughly $2 billion in funding via the CHIPS Act, which includes equity stakes in participating companies. The community is actively debating the sustainability of these gains, with many traders discussing potential short squeezes versus concerns that the valuations are detached from current revenue levels and future dilution risks.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending ahead of its quarterly earnings release as investors weigh aggressive expansion into hotel bookings and delivery against competitive concerns in the autonomous vehicle sector. The community is actively debating the company's valuation and the potential for long-term growth versus persistent short-term price stagnation.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is seeing intense debate as investors weigh strong year-over-year growth in user assets and trading volume against a recent uptick in operating expenses and net losses. While some community members are accumulating shares in anticipation of the upcoming removal of day trading restrictions and active buyback programs, others remain skeptical, citing continued spending pressure and historical price volatility.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending due to a major sector-wide catalyst involving the U.S. government's announcement of a multi-billion dollar quantum computing initiative. The community is actively debating the implications of IonQ's exclusion from this specific funding round, while long-term bulls argue its independent financial strength and strategic acquisitions solidify its position as a sector leader.

Hyliion Holdings Corp. engages in the development of sustainable electricity-producing technology. It focuses on providing modular power plant technology that can operate on various fuel sources through the KARNO power module. The company was founded by Thomas J. Healy in 2015 and is headquartered in Cedar Park, TX.

Hyliion Holdings Corporation - Ordinary Shares - Class A

Hyliion Holdings Corp

Hyliion Holdings Corp is seeing a massive surge in volume and investor interest as community members highlight its KARNO power module as a critical solution for AI data centers requiring native 800-volt DC efficiency. Sentiment is buoyed by speculative excitement regarding military and space-sector partnerships, though a vocal contingent of traders is actively warning of potential volatility and dilution risks following the rapid rally.

Dell Technologies, Inc. is a technology company, providing customers with a broad and innovative solution portfolio to help customers modernize their information technology (IT) infrastructure, address workforce transformation, and offer critical solutions that keep people and organizations connected. It operates through the following segments: Infrastructure Solutions Group (ISG) and Client Solutions Group (CSG). The ISG segment includes servers, networking, and storage, as well as services and third-party software and peripherals that are closely tied to the sale of ISG hardware. The CSG segment includes designs for commercial and consumer customers of desktops, thin client products, and notebooks. The company was founded by Michael Saul Dell in 1984 and is headquartered in Round Rock, TX.

Dell Technologies Inc - Ordinary Shares - Class C

Dell Technologies Inc

Dell Technologies is trending due to its pivotal role as a primary hardware supplier in the AI infrastructure supercycle, with community discourse driven by significant institutional contracts and aggressive strategic expansions into agentic AI. Investors are actively debating the company's valuation as it integrates into the AI enterprise stack, with many closely tracking its supply chain partnerships and institutional flow.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is seeing intense community debate driven by anticipation of upcoming earnings and potential reactions to shareholder meeting votes, particularly regarding authorization for reverse splits. Investors are closely monitoring prescription growth and GPO agreement impacts on commercial reach, while conflicting narratives between bullish expectations for the Tonmya launch and bearish concerns over cash burn and dilution continue to fuel heavy social media engagement.

Akari Therapeutics Plc is a clinical-stage biopharmaceutical company. It engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. The company was founded on October 7, 2004 and is headquartered in Tampa, FL.

Akari Therapeutics Plc - ADR

Akari Therapeutics

Akari Therapeutics is surging following positive preclinical data for its lead ADC program, AKTX-101, which demonstrated synergistic potential in treating KRAS-mutated pancreatic cancer. The community is actively discussing the stock's significant momentum and low-float volatility, with traders closely monitoring volume sustainability and key resistance levels as the company advances its oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy?

Key PointsADAR1 Capital Management added 829,963 shares of Crinetics Pharmaceuticals; estimated trade size $37.07 million based on quarterly average pricing...

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates

CRINETICS PHARM (CRNX) delivered earnings and revenue surprises of -0.82% and +42.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know

Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Jennison Associates LLC Sells 763,133 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Jennison Associates LLC reduced its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 37.3% in the fourth quarter, according to the company in its most recent Form 13F filing...

Analysts Estimate Crinetics Pharmaceuticals, Inc. (CRNX) to Report a Decline in Earnings: What to Look Out for

CRINETICS PHARM (CRNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pictet Asset Management Holding SA Has $72.63 Million Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX

Pictet Asset Management Holding SA lifted its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,560,300 shares of the...

Crinetics Pharmaceuticals (NASDAQ:CRNX) Given New $97.00 Price Target at Citizens Jmp

Citizens Jmp upped their target price on Crinetics Pharmaceuticals from $96.00 to $97.00 and gave the company a "market outperform" rating in a research report on Tuesday...

Impax Asset Management Group plc Buys Shares of 275,000 Crinetics Pharmaceuticals, Inc. $CRNX

Impax Asset Management Group plc bought a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) during the fourth quarter, according to the company in its most recent...

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Moderate Buy" by Analysts

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the ten research firms that are presently covering the...

Amneal Pharmaceuticals (AMRX) Q1 Earnings and Revenues Surpass Estimates

Amneal (AMRX) delivered earnings and revenue surprises of +63.64% and +1.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. The company was founded by R. Scott Struthers, Yun-Fei Zhu and Stephen F. Betz in 2008 and is headquartered in San Diego, CA.

Current Price	$37.01
Prev Close	$37.09
Open	$36.96
Dividend Yield	0.00%
50-Day Moving Average	$37.83
Beta	1.18
Avg. Volume	1.08M
PE Ratio	-7.23

52-Week High	$57.99
52-Week Low	$25.83
Market Capitalization	$3.91B
EPS (Annual)	-$4.95
Price to Book	3.05
Revenue Per Employee	$12,956.23

CRNX
Crinetics Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Compact View

Latest CRNX News

CRNXCrinetics Pharmaceuticals Inc